Combining serum protein concentrations to diagnose schizophrenia: A preliminary exploration

Journal of Clinical Psychiatry

Volumn 75, Issue 8, 2014, Pages e794-e801

  Xiong, Peng ^a   Zeng, Yong ^a   Wu, Qiuxia ^a   Huang, Diana Xiao Han ^b   Zainal, Hadzlinda ^b   Xu, Xiufeng ^a   Wan, Jing ^c   Xu, Fei ^a   Lu, Jin ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b HOSPITAL PULAU PINANG   (Malaysia)

^c The Third People's Hospital of Zhongshan   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; LITHIUM SALT; MYELIN BASIC PROTEIN; NERVE GROWTH FACTOR BETA SUBUNIT; OLANZAPINE; PROTEIN S100B; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR; VALPROIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR, HUMAN; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; NERVE GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DSM-IV-TR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; YOUNG MANIA RATING SCALE; BLOOD; CASE CONTROL STUDY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MYELIN BASIC PROTEIN; NERVE GROWTH FACTOR; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SCHIZOPHRENIA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84908311528     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08772     Document Type: Article

References (39)

1. Tamminga CA, Medoff DR. The biology of schizophrenia. Dialogues Clin Neurosci. 2000;2(4):339-348.
2. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-645.
3. Kendell RE, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry. 2003;160(1):4-12.
4. Bender S, Weisbrod M, Resch F. Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia? J Neural Transm. 2007;114(9):1199-1215.
5. Lawrie SM, Olabi B, Hall J, et al. Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia? World Psychiatry. 2011;10(1):19-31.
6. Schwarz E, Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol. 2008;153(suppl 1):S133-S136.
7. Arnone D, Cavanagh J, Gerber D, et al. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-Analysis. Br J Psychiatry. 2009;195(3):194-201.
8. Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008;34(1):9-12.
9. Levin Y, Wang L, Schwarz E, et al. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry. 2010;15(11):1088-1100.
10. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18(2):206-214.
11. Steffek AE, McCullumsmith RE, Haroutunian V, et al. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res. 2008;103(1-3):71-82.
12. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE. 2010;5(2):e9166.
13. Buckley PF, Mahadik S, Pillai A, et al. Neurotrophins and schizophrenia. Schizophr Res. 2007;94(1-3):1-11.
14. Marx CE, Jarskog LF, Lauder JM, et al. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry. 2001;50(10):743-749.
15. Miller BJ, Buckley P, Seabolt W, et al. Meta-Analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663-671.
16. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008;85(1):1-74.
17. Yelmo-Cruz S, Morera-Fumero AL, Abreu-Gonzalez P. S100B and schizophrenia. Psychiatry Clin Neurosci. 2013;67(2):67-75.
18. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res. 2010;44(3):149-156.
19. Notturno F, Capasso M, DeLauretis A, et al. Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies. Muscle Nerve. 2009;40(1):50-54.
20. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17(5):494-502.
21. Manev H, Manev R. S100B: An old neurotrophic factor with putative new roles in psychiatric illnesses. J Psychiatr Res. 2001;35(6):347-350.
22. van Beveren NJ, van der Spelt JJ, de Haan L, et al. Schizophrenia-Associated neural growth factors in peripheral blood: A review. Eur Neuropsychopharmacol. 2006;16(7):469-480.
23. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362(9386):798-805.
24. Xiong P, Zeng Y, Wan J, et al. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011;189(1):72-76.
25. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSMIV- TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435.
29. Huberty CJ, Hussein MH. Some problems in reporting use of discriminant analysis. J Exp Educ. 2003;71(2):177-192.
30. de Souza DF, Wartchow K, Hansen F, et al. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:14-22.
31. Martinotti G, Di Iorio G, Marini S, et al. Nerve growth factor and brainderived neurotrophic factor concentrations in schizophrenia: A review. J Biol Regul Homeost Agents. 2012;26(3):347-356.
32. Parikh V, Evans DR, Khan MM, et al. Nerve growth factor in nevermedicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res. 2003;60(2-3):117-123.
33. Huang TL, Lee CT. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res. 2006;40(7):664-668.
34. Schnieder TP, Dwork AJ. Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry. 2011;69(2):134-139.
35. Li S, Wu H, Guo H, et al. Neuron-specific enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia. J Huazhong Univ Sci Technolog Med Sci. 2006;26(2):228-230.
36. Kunz M, Cereser KM, Goi PD, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- And anti-inflammatory balance. Rev Bras Psiquiatr. 2011;33(3):268-274.
37. Schroeter ML, Abdul-Khaliq H, Fruhauf S, et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res. 2003;62(3):231-236.
38. Kim YK, Myint AM, Verkerk R, et al. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123-129.
39. Sarro S, Duenas RM, Ramirez N, et al. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophr Res. 2004;68(2-3):349-356.